Form 4 for AARD Aardvark Therapeutics, Inc.
Accepted 2026-09-11 20:14:00 ET · period of report 2026-09-10 · accession 0001193125-26-389564 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-09-11 20:14 | 2026-09-10+ | AARD | Sun Nelson | See Remarks | S - Sale | $5.15 | -76.8K | 35.5K | -68% | -$395.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.00001 per share | 2026-09-10 | S | D | 14,754 | $5.00 | 97,475 | D | — | — | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. (F2) The price reported in Column 4 reflects the weighted-average sales price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.0007, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. (F3) Includes 3,745 shares of common stock acquired pursuant to the Issuer's 2025 Employee Stock Purchase Plan on May 22, 2026. |
| 2 | Common | Common Stock, par value $0.00001 per share | 2026-09-11 | S | D | 62,000 | $5.18 | 35,475 | D | — | — | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026. |